Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD)
Latest Information Update: 18 Sep 2025
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms CHRONICLES COPD
- Sponsors AstraZeneca
Most Recent Events
- 07 Feb 2025 Planned End Date changed from 29 Aug 2025 to 31 Mar 2026.
- 07 Feb 2025 Planned primary completion date changed from 29 Aug 2025 to 31 Mar 2026.
- 05 Nov 2024 Status changed from not yet recruiting to recruiting.